Nextage Therapeutics (XTAE:NXTG) EBIT: ₪-11.17 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:NXTG Nextage Therapeutics Ltd XTAE:NXTG
8 GF Score
Price ₪0.39
GF Value ₪0.31
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Nextage Therapeutics EBIT?

Nextage Therapeutics XTAE:NXTG 8 EBIT is ₪-11.17 Mil as of Dec. 2025. GuruFocus rates XTAE:NXTG with a GF Score™ of 8/100 and a GF Value™ of ₪0.31 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Nextage Therapeutics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was ₪-13.53 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was ₪-11.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nextage Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 was -18.14%. Nextage Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,956.60%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nextage Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -23.09%.

Nextage Therapeutics  (XTAE:NXTG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nextage Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-10.844 * ( 1 - 0% )/( (54.966 + 64.613)/ 2 )
=-10.844/59.7895
=-18.14 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=46.836 - 13.332 - ( 0.167 - max(0, 22.905 - 1.443+0.167))
=54.966

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=46.139 - 8.564 - ( 0.279 - max(0, 28.723 - 1.685+0.279))
=64.613

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Nextage Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-27.05/( ( (1.725 + max(-12.75, 0)) + (1.04 + max(-13.62, 0)) )/ 2 )
=-27.05/( ( 1.725 + 1.04 )/ 2 )
=-27.05/1.3825
=-1,956.60 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.763 + 0 + 0.039) - (13.332 + 0 + 0.22)
=-12.75

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.901 + 0 + 0.058) - (8.564 + 0 + 6.015)
=-13.62

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nextage Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-11.165/48.357
=-23.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nextage Therapeutics EBIT Related Terms

Nextage Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Nextage Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nextage Therapeutics EBIT Chart

Nextage Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.91 -5.98 -7.43 -7.70 -11.17

Nextage Therapeutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.17 -3.56 -4.13 2.36 -13.53

XTAE:NXTG vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nextage Therapeutics EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nextage Therapeutics's EV-to-EBIT falls into.


XTAE:NXTG
8GF Score
Nextage Therapeutics Ltd XTAE:NXTG
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nextage Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪-11.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₪-11.17 Mil mean?
Nextage Therapeutics (XTAE:NXTG) has a EBIT of ₪-11.17 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nextage Therapeutics.
Is Nextage Therapeutics' EBIT too high?
Nextage Therapeutics' current EBIT is ₪-11.17 Mil. Overall, Nextage Therapeutics has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nextage Therapeutics' EBIT compare to ZTS and UTHR?
Nextage Therapeutics' EBIT of ₪-11.17 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nextage Therapeutics. Nextage Therapeutics's current EBIT is ₪-11.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextage Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nextage Therapeutics (XTAE:NXTG) is currently considered Modestly Overvalued. The stock's GF Value™ is ₪0.31, compared to a current price of ₪0.39 — trading 25.8% above its estimated fair value. The current EBIT is ₪-11.17 Mil. Nextage Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Nextage Therapeutics (XTAE:NXTG), the current EBIT is ₪-11.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nextage Therapeutics (XTAE:NXTG) Overvalued in 2026?

Based on GuruFocus' analysis, Nextage Therapeutics stock appears to be overvalued. The current stock price of ₪0.39 is trading 25.8% above its estimated GF Value™ of ₪0.31. GuruFocus considers Nextage Therapeutics to be Modestly Overvalued.

Key valuation signals for XTAE:NXTG:

  • EBIT: ₪-11.17 Mil
  • GF Value™: ₪0.31 vs. price of ₪0.39 (25.8% above fair value)
  • GF Score™: 8/100 with 4 warning signs

No single metric tells the full story. See the XTAE:NXTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nextage Therapeutics Business Description

Address Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
8GF Score

Get the complete analysis for XTAE:NXTG

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.39
Price
₪0.31
GF Value